• In vivo modelling of chemo-resistant neuroblastoma provides new insights into chemo-refractory disease and metastasis. 

  Yogev, O; Almeida, GS; Barker, KT; George, SL; Kwok, C; Campbell, J; Zarowiecki, M; Kleftogiannis, D; Smith, LM; Hallsworth, A; Berry, P; Möcklinghoff, T; Webber, HT; Danielson, LS; Buttery, B; Calton, EA; da Costa, BM; Poon, E; Jamin, Y; Lise, S; Veal, GJ; Sebire, N; Robinson, SP; Anderson, J; Chesler, L (2019-08-12)

  Neuroblastoma is a pediatric cancer that is frequently metastatic and resistant to conventional treatment. In part, a lack of natively metastatic, chemoresistant in vivo models has limited our insight into the development ...
• Interim Results from the IMPACT Study: Evidence for prostate specific antigen screening in BRCA2 mutation Carriers 

  Eeles, R (Elsevier, 2019-09-17)
• Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study. 

  Nyberg, T; Frost, D; Barrowdale, D; Evans, DG; Bancroft, E; Adlard, J; Ahmed, M; Barwell, J; Brady, AF; Brewer, C; Cook, J; Davidson, R; Donaldson, A; Eason, J; Gregory, H; Henderson, A; Izatt, L; Kennedy, MJ; Miller, C; Morrison, PJ; Murray, A; Ong, K-R; Porteous, M; Pottinger, C; Rogers, MT; Side, L; Snape, K; Walker, L; Tischkowitz, M; Eeles, R; Easton, DF; Antoniou, AC (2019-09-05)

  BACKGROUND: BRCA1 and BRCA2 mutations have been associated with prostate cancer (PCa) risk but a wide range of risk estimates have been reported that are based on retrospective studies. OBJECTIVE: To estimate relative and ...
• Aggressive fibromatosis response to tamoxifen: lack of correlation between MRI and symptomatic response. 

  Libertini, M; Mitra, I; van der Graaf, WTA; Miah, AB; Judson, I; Jones, RL; Thomas, K; Moskovic, E; Szucs, Z; Benson, C; Messiou, C (2018)

  Background: One of the commonly used systemic agents for the treatment of aggressive fibromatosis is the anti-oestrogen drug tamoxifen. However, data on efficacy and optimum methods of response assessment are limited, ...
• Compartmental Model for 223Ra-Dichloride in Patients With Metastatic Bone Disease From Castration-Resistant Prostate Cancer. 

  Taprogge, J; Murray, I; Gear, J; Chittenden, SJ; Parker, CC; Flux, GD (2019-07-23)

  PURPOSE: 223Ra-Dichloride is used for treatment of patients with metastatic bone disease from castration-resistant prostate cancer. The uptake and mechanism of action of 223Ra-Dichloride is not well understood. The aim of ...

View more